Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy

Company Overview - Supernus Pharmaceuticals (SUPN) currently holds a Momentum Style Score of B, indicating potential for strong performance based on recent trends [3] - The company has a Zacks Rank of 1 (Strong Buy), which is associated with a historical outperformance in the market [4] Price Performance - Over the past week, SUPN shares have increased by 5.3%, while the Zacks Medical - Generic Drugs industry has only risen by 0.77% [6] - In a longer time frame, SUPN's shares have shown an 11.26% monthly price change compared to the industry's 10.78% [6] - Over the past quarter, SUPN shares have surged by 41.67%, and over the last year, they have gained 54.65%, significantly outperforming the S&P 500, which increased by 8.19% and 19.61% respectively [7] Trading Volume - The average 20-day trading volume for SUPN is 711,004 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, two earnings estimates for SUPN have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $2.18 to $2.55 [10] - For the next fiscal year, two estimates have also moved upwards without any downward revisions [10] Conclusion - Considering the positive price trends, strong earnings outlook, and favorable trading volume, SUPN is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a compelling option for investors seeking short-term gains [12]